Anticoagulant Safety Remains a Problem

Emergency Hospitalizations for Adverse Drug Events

Comparative Pharmacology

Inducers and Inhibitors of Cytochrome P450 3A4 and P-gp

Novel Anticoagulants for Stroke Prevention in AF

Trials With NOACs vs Warfarin in AF

All NOACs and Stroke or SE Event

ENGAGE AF-TIMI 48: Primary End Point Stroke/Systemic Embolic Event (2.8-y median

follow-up)

ENGAGE AF-TIMI 48 Bleeding

Who Should Remain on Warfarin?

EINSTEIN DVT/PEStudy Designs

Switching From Warfarin to NOACs

Adverse Events

SummaryBenefits of NOACs

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)